Literature DB >> 12127997

Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1 in Peyronie's disease.

Ching Shwun Lin1, Guiting Lin, Zhong Wang, Suzan A Maddah, Tom F Lue.   

Abstract

Peyronie's disease (PD) is characterized by fibrosis in the tunica albuginea (TA) of the penis, which becomes bent as a result. We have previously shown that transforming growth factor-beta 1 (TGF-beta1) is upregulated in the TA of patients with PD and can initiate PD-like lesions in rat models. In this study we isolated three types of fibroblasts: P cells from the lesions of PD patients, C cells from the normal-appearing areas of the TA of the same patients, and N cells from the TA of patients without PD. We examined these cells for the expression of two fibrogenic cytokines, connective tissue growth factor (CTGF), and Monocyte Chemoattractant Protein 1 (MCP-1). We found that CTGF was expressed at similar levels in P, C, and N cells, whereas MCP-1 was significantly more expressed in P cells than in C cells and more in C cells than in N cells. Higher MCP-1 expression was also found in the lesions than in normal TA. Treatment with TGF-beta1-induced higher expression of MCP-1 but not CTGF in all three types of cells, with C cells being the most responsive. Based on these observations, we propose that MCP-1 could be a novel therapeutic target in PD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12127997     DOI: 10.1016/s0006-291x(02)00765-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  The Genetic Basis of Peyronie Disease: A Review.

Authors:  Amin S Herati; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2016-01-08

2.  Mesenchymal stem cell marker Stro-1 is a 75 kd endothelial antigen.

Authors:  Hongxiu Ning; Guiting Lin; Tom F Lue; Ching-Shwun Lin
Journal:  Biochem Biophys Res Commun       Date:  2011-08-27       Impact factor: 3.575

3.  Intratunical injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie's disease.

Authors:  Fabio Castiglione; Petter Hedlund; Frank Van der Aa; Trinity J Bivalacqua; Patrizio Rigatti; Hein Van Poppel; Francesco Montorsi; Dirk De Ridder; Maarten Albersen
Journal:  Eur Urol       Date:  2012-09-24       Impact factor: 20.096

4.  Upregulation of mRNA expression of MCP-1 by TGF-beta1 in fibroblast cells from Peyronie's disease.

Authors:  Carolin Szardening-Kirchner; Lutz Konrad; Ekkehard W Hauck; Simone M Haag; Oliver Eickelberg; Wolfgang Weidner
Journal:  World J Urol       Date:  2008-08-14       Impact factor: 4.226

5.  Antioxidant Mechanism of Xiaojin Pill () for Treatment of Peyronie's Disease in Rats Based on Matrix Metalloproteinases.

Authors:  Qiang Geng; Fu Wang; Qiang Han; Shao-Feng Chen; Bin Ouyang; Zhong Li; Yu Zhao; Qing-He Gao; Guo-Jin Yu; Jun Guo
Journal:  Chin J Integr Med       Date:  2019-10-24       Impact factor: 1.978

6.  Current and emerging treatment options for Peyronie's disease.

Authors:  Ahmet Gokce; Julie C Wang; Mary K Powers; Wayne Jg Hellstrom
Journal:  Res Rep Urol       Date:  2013-01-14

7.  Connective tissue growth factor (CTGF/CCN2) is negatively regulated during neuron-glioblastoma interaction.

Authors:  Luciana F Romão; Fabio A Mendes; Natalia M Feitosa; Jane Cristina O Faria; Juliana M Coelho-Aguiar; Jorge Marcondes de Souza; Vivaldo Moura Neto; José Garcia Abreu
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

Review 8.  New discoveries in the basic science understanding of Peyronie's disease.

Authors:  Mark Jalkut; Nestor Gonzalez-Cadavid; Jacob Rajfer
Journal:  Curr Urol Rep       Date:  2004-12       Impact factor: 2.862

9.  Expression of transforming growth factor-beta (TGF-beta) in chronic idiopathic cough.

Authors:  Shaoping Xie; Patricia Macedo; Mark Hew; Christina Nassenstein; Kang-Yun Lee; Kian Fan Chung
Journal:  Respir Res       Date:  2009-05-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.